Thrombate III® (Human)

Thrombate III® is indicated for the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.  

Subjects with AT-III deficiency should be informed about the risk of thrombosis in connection with pregnancy and surgery and about the inheritance of the disease.

The diagnosis of hereditary antithrombin III (AT-III) deficiency should be based on a clear family history of venous thrombosis as well as decreased plasma AT-III levels, and the exclusion of acquired deficiency.

AT-III in plasma may be measured by amidolytic assays using synthetic chromogenic substrates, by clotting assays, or by immunoassays.  The latter does not detect all hereditary AT-III deficiencies.

The AT-III level in neonates of parents with hereditary AT-III deficiency should be measured immediately after birth. (Fatal neonatal thromboembolism, such as aortic thrombi in children of women with hereditary anti-thrombin III deficiency, has been reported)

Plasma levels of AT-III are lower in noenates than adults, averaging approximately 60% in normal term infants.  AT-III levels in premature infants may be much lower.  Low plasma AT-III levels, especially in a premature infant, therefore, do not necessarily indicate hereditary deficiency.  It is recommended that testing and treatment with Thrombate® III of neonates be discussed with an expert on coagulation.

Thrombate III® (Human) ‐ Grifols

500 iu vial
NDC #: